All In Biotech

NDA 021313 · Organon LLC

Clarinex-D 12 Hour

Desloratadine, Pseudoephedrine Sulfate · Oral · Histamine-1 Receptor Antagonist

Last checked: Nov 20, 2026Latest source record: Mar 15, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Feb 1, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

87

28 Phase 3, 4 recruiting

FAERS reports

39

23 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 12, 2025.

CLARINEX-D 12 HOUR is a combination product containing a histamine-1 (H1) receptor antagonist and an alpha adrenergic agonist indicated for: Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. ( 1.1 ) 1.1 Seasonal Allergic Rhinitis CLARINEX-D ® 12 HOUR Extended Release Tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. CLARINEX-D 12 HOUR Extended Release Tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see Clinical Pharmacology (12) ].

Mechanism: Desloratadine is a long acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor-binding study in guinea pigs showed that desloratadine does not readily cross the blood brain barrier. The clinical significance of this...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 1, 2006 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLabelLetter
1 products under this application
  • CLARINEX-D 12 HOUR · DESLORATADINE 2.5MG; PSEUDOEPHEDRINE SULFATE 120MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Desloratadine" as an intervention, any sponsor and status, largest first.

All 87 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity4
  • nausea4
  • dizziness3
  • feeling abnormal3
  • insomnia3
  • malaise3
  • product dose omission issue3
  • pruritus3
  • rash3
  • urticaria3
  • abdominal discomfort2
  • anxiety2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20081
20092
20107
20112
20122
20131
20155
20163
20171
20182
20194
20211
20223
20232
20241
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Clarinex-D 12 Hour (Desloratadine/Pseudoephedrine)

2024 spending

$733K

Beneficiaries

397

1,225 claims

Per beneficiary

$1,846

$5.43 per unit

View as table
YearSpending
2020$0
2021$126,541
2022$690,361
2023$764,353
2024$732,826

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 190 on PubMed

Sponsor: Organon LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.